Literature DB >> 3678823

Factors that interact with the rat albumin promoter are present both in hepatocytes and other cell types.

L E Babiss1, R S Herbst, A L Bennett, J E Darnell.   

Abstract

The rat albumin promoter inserted in adenovirus directs transcription in human and rodent hepatoma cells and in rodent hepatocytes (Friedman et al. 1986) and Babiss et al. (1986) but not in HeLa cells or myeloma cells. The nucleotides between -43 and -156 of the RNA start site of the rat albumin gene are required for this cell-specific expression. Protein binding studies (footprints, exonuclease III stops, and gel shifts) all indicate specific interaction in the -80 to -130 region of the gene with factors present in nuclear extracts of hepatocytes and hepatomas, but also from extracts of other cells that do not express the albumin gene. To observe albumin promoter binding, a smaller amount of extract of liver cell nuclei was required compared to extracts of HeLa cell or kidney cell nuclei. In addition, the various tests of DNA-protein interaction did not give qualitatively identical results with extracts from different cells. However, it seems clear that factors are present in several cell types where albumin genes are inactive that will bind to those DNA sequences demonstrated to be necessary for cell-specific expression of this gene. These factors could either be similar but nonidentical factors or the same factors that are modified differently in different cell types.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3678823     DOI: 10.1101/gad.1.3.256

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  30 in total

1.  The rat albumin promoter: cooperation with upstream elements is required when binding of APF/HNF1 to the proximal element is partially impaired by mutation or bacterial methylation.

Authors:  F Tronche; A Rollier; I Bach; M C Weiss; M Yaniv
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

2.  The cellular transcription factor E2f requires viral E1A and E4 gene products for increased DNA-binding activity and functions to stimulate adenovirus E2A gene expression.

Authors:  L E Babiss
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  The mouse albumin enhancer contains a negative regulatory element that interacts with a novel DNA-binding protein.

Authors:  R S Herbst; E M Boczko; J E Darnell; L E Babiss
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

4.  Binding of a liver-specific factor to the human albumin gene promoter and enhancer.

Authors:  M Frain; E Hardon; G Ciliberto; J M Sala-Trepat
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

5.  The rat albumin promoter is composed of six distinct positive elements within 130 nucleotides.

Authors:  P Herbomel; A Rollier; F Tronche; M O Ott; M Yaniv; M C Weiss
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

6.  The cell-specific enhancer of the mouse transthyretin (prealbumin) gene binds a common factor at one site and a liver-specific factor(s) at two other sites.

Authors:  R H Costa; E Lai; D R Grayson; J E Darnell
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

7.  Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes.

Authors:  R H Costa; D R Grayson; J E Darnell
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

8.  Multiple hepatic trans-acting factors are required for in vitro transcription of the human alpha-1-antitrypsin gene.

Authors:  Y Li; R F Shen; S Y Tsai; S L Woo
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

9.  A promoter-linked coupling region required for stimulation of alpha-fetoprotein transcription by distant enhancers.

Authors:  P Wen; N Crawford; J Locker
Journal:  Nucleic Acids Res       Date:  1993-04-25       Impact factor: 16.971

10.  Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia.

Authors:  D A Brenner; M Buck; S P Feitelberg; M Chojkier
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.